|
KMID : 1009020100080030137
|
|
Clinical Psychopharmacology and Neuroscience
2010 Volume.8 No. 3 p.137 ~ p.143
|
|
|
Association of GSK-3β?50T/C Polymorphism with Depression and Cognitive Impairment in Patients with Schizophrenia
|
|
Lee Jung-Goo
Lee Sun-Jung
Park Sung-Woo
Kim Min-Chul
Jung Sung-Soo
Kim Young-Hoon
|
|
|
Abstract
|
|
|
Objective: In this study, authors wanted to find out the association between the glycogen synthase kinase-3β (GSK-3β) ?50T/C polymorphism and depression and cognitive impairment in patients with schizophrenia. 207 schizophrenia and 100 normal subjects were participated. We evaluated Brief Psychiatric Rating Scale (BPRS), the Hamilton Depression Rating Scale (HAM-D), and the Korean version of the Mini Mental Status Examination (K-MMSE) in schizophrenia.
Methods: Polymerase chain reaction (PCR) analysis of genomic DNA was conducted to evaluate the genotype distribution and allele frequency of GSK-3β ?50T/C in subjects.
Results: We observed that genotype distribution and allele frequency were not significantly different between schizophrenia and normal subjects. Moreover, no significant difference was found in the promoter polymorphism of GSK-3β in compound genotype distributions and allele frequencies in schizophrenia according to HAM-D scores. However, there was a difference in genotype distribution and allele frequency in schizophrenia according to cognitive impairment.
Conslusion: These results suggest that the GSK-3β ?50T/C gene polymorphism may be associated with cognitive impairment in patients with schizophrenia.
|
|
|
KEYWORD
|
|
|
Schizophrenia, Glycogen synthase kinase-3β, Cognition, Depression, Polymorphism
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|